Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 17/20 | 0.76 |
| ▸ | ADORA2A | P29274 | 13/20 | 0.76 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.51 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.51 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1566228 | 0.98 | ADORA1 (0.80) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL1566014 | 0.87 | ADORA1 (0.78) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL1566038 | 0.86 | ADORA1 (1.00) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL1565701 | 0.85 | ADORA1 (0.82) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL1566051 | 0.84 | ADORA1 (0.77) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL1567047 | 0.83 | ADORA1 (0.66) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL1565512 | 0.83 | ADORA1 (0.76) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL1565435 | 0.82 | ADORA1 (0.91) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL1567053 | 0.82 | ADORA1 (0.74) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL1565194 | 0.82 | ADORA1 (0.80) | ADORA1ADORA2AADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305684-A1 | Poycyloalkylpurines as adenosine receptor antagonists | Biogen Idec MA Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| US-20100063071-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | BIOGEN IDEC MA INC. | 2010-03-11 | — | — | US | disclosed |
| US-20090221821-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-7579354-B2 | Adenosine receptor antagonists and methods of making and using the same | KIESMAN WILLIAM F | 2009-08-25 | — | — | US | disclosed |
| EP-2070930-A1 | Polycycloalkylpurines as adenosine receptor antagonists | Biogen Idec MA, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1230243-B1 | POYCYLOALKYLPURINES AS ADENOSINE RECEPTOR ANTAGONISTS | BIOGEN IDEC INC (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20070015732-A1 | Adenosine receptor antagonists and methods of making and using the same | KIESMAN WILLIAM F | 2007-01-18 | — | — | US | disclosed |
| US-20060252730-A1 | Adenosine receptor antagonists and methods of making and using the same | KIESMAN WILLIAM F | 2006-11-09 | — | — | US | disclosed |
| US-20040067966-A1 | Adenosine receptor antagonists and methods of making and using the same | BIOGEN, INC. | 2004-04-08 | — | — | US | disclosed |
| US-6649600-B1 | 2,6-Dioxo or dithioxy-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo derivatives; highly potent and selective diuretics | BIOGEN, INC. | 2003-11-18 | — | — | US | disclosed |
| EP-1230243-A1 | POYCYLOALKYLPURINES AS ADENOSINE RECEPTOR ANTAGONISTS | BIOGEN, INC. (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001034610-A1 | POLYCYCLOALKYLPURINES AS ADENOSINE RECEPTOR ANTAGONISTS | BIOGEN, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221821-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA2A 2/4885ADORA2B 4/4885 |
| US-20060252730-A1 | Adenosine receptor antagonists and methods of making and using the same | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA2A 2/4885ADORA2B 4/4885 |
| US-20070015732-A1 | Adenosine receptor antagonists and methods of making and using the same | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA2A 2/4885ADORA2B 4/4885 |
| US-20100063071-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | ADORA2A, P2RX3, P2RX6 | ADORA1 8/4885ADORA2A 1/4885ADORA2B 12/4885 |
| US-20040067966-A1 | Adenosine receptor antagonists and methods of making and using the same | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA2A 2/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.